Editas Medicine (EDIT) logo

Editas Medicine (EDIT) stock

Gene editing medicines , market cap $264M

After-hours Fri
$1.66
+1.22%

Close $1.64 -4.09%

Why is EDIT down?

Down 40% from Nov 9 to Nov 20 while the S&P 500 fell 8%.

  • Editas Medicine fell 40% from Nov 9 to Nov 20 while biotech stocks fell a median 12%: it trailed its group by 28 points.

Sources: Price history, Nov 20, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time EDIT moves

Free account, no card. An optional alert when EDIT moves or its score changes.Pro, $1 for a first month. An optional alert when EDIT moves or its score changes.Pro, 7 days free with a card. An optional alert when EDIT moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on EDIT →The other side, the timeline, and its peers, for Pro members.
Quality Score
-8
Poor
In its industry
#235of 273
Checks firing
0of 14
Trending down
From 52-week high
-58.4%
under its best in a year

EDIT's Quality Score fell 1 point on Fri, Nov 20, to -8. Its market value fell under $300M ($264M).

Follow EDIT's trial news. Pro members can get an alert when Editas Medicine files news, and see its trials, share raises, and its CEO's filings.

Get an alert when EDIT files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“The Company remains on track to begin patient dosing this year…”Trial start · SEC filing · Nov 9
Cash$190M, about 6 quarters at the last year's spendingOn Sep 30 · the company says “into second half of 2028”

Key facts on EDIT

Key facts on EDIT
Holding it back70.5% more shares than a year ago
Latest filing8-K, Nov 9 Reported its quarterly results

EDIT in the news

Mon Nov 9Editas Medicine reported a loss of $0.15 a share SEC, 7:04 AM ET EDIT closed +7.0% that day.

What's next

Mon Nov 30: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$190M, about 6 quarters at the last year's spendingOn Sep 30 · the company says “into second half of 2028”

EDIT catalysts

Coming up

After its last 4 reports it closed +7.5% on average, higher 4 of 4 times.

11 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for EDIT, and how long its cash lasts

Next step the company has named

2026“The Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027.”Trial start · SEC filing · Nov 9

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein CholesterolPhase 1/2 · Not yet recruiting · 56 people · main data estimated Jun 2029 · NCT07894887

2 more trials, 3 more milestones and 39 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 6 quarters

$190M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into second half of 2028” (8-K, Nov 9).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Aug 31, 2026)
  • At-the-market share sales program (S-3, filed Aug 31, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CEO Neil O'Neill Gilmore sold 21,164 shares on Nov 11, under a planned sale. 12 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Neil Gilmore’s 12 filings and quotes.

Get an alert when EDIT files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How EDIT ranks in Biotech

EDIT is #235 of 273 by Quality Score.

How EDIT ranks in Biotech
RankStockQuality Score
235Editas Medicine (EDIT) logoEDITEditas Medicine-8

Share count against a year before: EDIT +70%, BEAM +2.1%, NTLA +27%.

More in Biotech

When does EDIT report earnings, and what happens after?

Expected to report Mon Mar 8, before the open (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What EDIT reported on Nov 9, 2026

The quarter

A loss of $0.15 a share, from $0.28.

“The increase was primarily attributable to revenue recognized in connection with clinical development milestones achieved by a strategic partner.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

EDIT's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase was primarily attributable to higher intellectual property and patent-related fees due to increased legal activity related to intellectual property defense.”

From its results filing (SEC filing · Nov 9)

The numbers

Market value
$264M
today
Sales
$49.8M
up 7.4% on the year
Free cash flow
-$110M
last 12 months

Sales fell 15% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 8.7% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on EDIT: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+1.3%+5.5%+7.0%
May 5Aug 5Nov 9
ReportedGapReaction5
days
Nov 9, 2026Before open+2.7%+7.0%-15.6%
Aug 5, 2026After close+2.5%+5.5%+3.3%
May 5, 2026Before open+0.7%+1.3%+2.0%

EDIT closed higher after 4 of its last 4 reports.

All 4 reports, and EDIT's Quality Score going into each

EDIT sales and profit by year

Sales and profit by year

Sales grew in three of the last seven years, to $40.5M in 2025. It lost money in each of the eight years.

Nothing is firing on EDIT right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on EDIT, and all 14 on every stock.Get in free →See the top 3 →Start Pro

EDIT RSI on Nov 20: 28.6, below its 50-day and 200-day averages

Not scored

RSI 28.6, MACD below signal, below both averages. Not scored.

The deep dive on EDIT

  • What it does and how it makes money3 findingsAn operating loss of $160M in fiscal 2025, on $40.5M of sales.Annual report, filed Mar 9, 2026"We are entitled to receive high single-digit to low double-digit percentage royalties on net sales made by BMS , its affiliates and sublicensees of any BMS Licensed Products, subject to reductions in certain circumstances." (10-K for fiscal 2025)SEC filing · Mar 9, 2026
  • Where it stands4 findingsFor Pro members4 findings on where EDIT stands: its cash, debt, and share count, for Pro members
  • What changed in its filings8 findings"On June 6, 2023, Merck & Co., Inc., filed a lawsuit against HHS and CMS asserting that, among other things, the IRA’s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution." (10-K for fiscal 2025)SEC filing · Mar 9, 2026A new heading in its "Risk Factors" this year: "Unfavorable national or global economic conditions or political developments could adversely affect our business, financial condition or results of operations." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 9, 2026, against the one of Mar 5, 2025
  • Who holds and trades it1 findingFor Pro members1 finding on who holds and trades EDIT, for Pro members
  • Against its closest peers2 peersShare count against a year before: EDIT +70%, BEAM +2.1%, NTLA +27%.

12 more findings on EDIT, each with its source, for Pro members.

EDIT share count over time

71% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of EDIT outstanding, as filed
Shares
outstanding
As
of
154.3MNov 6, 2026
153.6MJul 31, 2026
97.9MApr 29, 2026
97.9MFeb 27, 2026
Offerings, shelves, and splits of EDIT, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3)Aug 31, 2026
Raised $125M in a sale of shares, about 47% of its market valueMay 26, 2026
Registered shares for a later sale (S-3ASR)Feb 28, 2024

EDIT's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold EDIT?

In ETFs: EDIT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

87 employeesCambridge, MAeditasmedicine.com

What Editas Medicine says it competes with

“The biotechnology and pharmaceutical industries, including in the gene therapy, gene editing and cell therapy fields, are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property and proprietary products.”

From its annual report, SEC filing · Mar 9, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on EDIT and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn EDIT's score around: 9 things
  • 6 more filings explained, a plain line each
  • 4 more things pulling EDIT's score down

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: EDIT's Quality Score is -8 (Poor), #235 of 273 in Biotech.

What does EDIT's Quality Score say?

EDIT scores -8 today, which Breakaway calls Poor. It is #235 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 40% from Nov 9 to Nov 20 while the S&P 500 fell 8%. Cash lasts about 6 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is EDIT's Quality Score?

EDIT scores -8 today, which Breakaway calls Poor (below zero). That is #235 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind EDIT's -8.

When does EDIT report earnings?

Expected to report Mon Mar 8, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. EDIT closed higher after 4 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Editas Medicine: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.